A Phase 1, Randomized, Double-Blind, Single-Dose Escalation Study and Multiple-Dose Escalation Study of VX-509 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2012
At a glance
- Drugs Decernotinib (Primary)
- Indications Rheumatic disorders
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
- 27 Apr 2009 New trial record.